- Home
- FTRK vs UNCY Comparison
FTRK vs UNCY Comparison
Compare FTRK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRK
- UNCY
- Stock Information
- Founded
- FTRK 2012
- UNCY 2016
- Country
- FTRK Singapore
- UNCY United States
- Employees
- FTRK N/A
- UNCY N/A
- Industry
- FTRK
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- FTRK
- UNCY Health Care
- Exchange
- FTRK NYSE
- UNCY Nasdaq
- Market Cap
- FTRK 102.2M
- UNCY 91.0M
- IPO Year
- FTRK 2025
- UNCY 2021
- Fundamental
- Price
- FTRK $4.58
- UNCY $0.68
- Analyst Decision
- FTRK
- UNCY Strong Buy
- Analyst Count
- FTRK 0
- UNCY 4
- Target Price
- FTRK N/A
- UNCY $6.38
- AVG Volume (30 Days)
- FTRK 2.0M
- UNCY 6.5M
- Earning Date
- FTRK 01-01-0001
- UNCY 05-14-2025
- Dividend Yield
- FTRK N/A
- UNCY N/A
- EPS Growth
- FTRK N/A
- UNCY N/A
- EPS
- FTRK N/A
- UNCY N/A
- Revenue
- FTRK $117,230.00
- UNCY N/A
- Revenue This Year
- FTRK N/A
- UNCY N/A
- Revenue Next Year
- FTRK N/A
- UNCY $1,458.53
- P/E Ratio
- FTRK N/A
- UNCY N/A
- Revenue Growth
- FTRK 2589.48
- UNCY N/A
- 52 Week Low
- FTRK $3.15
- UNCY $0.20
- 52 Week High
- FTRK $9.69
- UNCY $1.10
- Technical
- Relative Strength Index (RSI)
- FTRK N/A
- UNCY 48.23
- Support Level
- FTRK N/A
- UNCY $0.47
- Resistance Level
- FTRK N/A
- UNCY $0.66
- Average True Range (ATR)
- FTRK 0.00
- UNCY 0.10
- MACD
- FTRK 0.00
- UNCY -0.01
- Stochastic Oscillator
- FTRK 0.00
- UNCY 23.83
About FTRK FAST TRACK GROUP
Fast Track Group is a regional entertainment-focused event management and marketing company that provides a full range of services including experiential marketing, artiste endorsement and management, movie premiere organizations, grand openings, and concerts. It also creates, develops, organizes, hosts, and manages various events and concerts.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.